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Abstract
Polymorphisms in the cytochrome P450 1B1 (CYP1B1) and glutathione S-transferase (GST) drug
metabolic enzymes, which are responsible for metabolic activation/detoxification of estrogen and
environmental carcinogens, were analyzed for their association with breast cancer risk in 541
cases and 635 controls from a North Carolina population. Each polymorphism, altering the
catalytic function of their respective enzymes, was analyzed in Caucasian and African-American
women. As reported in previous studies, individual polymorphisms did not significantly impact
breast cancer risk in either Caucasian or African-American women. However, African-American
women exhibited a trend towards a protective effect when they had at least one CYP1B1 119S
allele (OR=0.53; 95% CI=0.20–1.40) and increased risk for those women harboring at least one
CYP1B1 432V allele (OR=5.52; 95% CI=0.50–61.37). Stratified analyses demonstrated
significant interactions in younger (age ≤60) Caucasian women with the CYP1B1 119SS genotype
(OR=3.09; 95% CI=1.22–7.84) and younger African-American women with the GSTT1 null
genotype (OR=4.07; 95% CI=1.12–14.80). A notable trend was also found in Caucasian women
with a history of smoking and at least one valine allele at GSTP1 114 (OR=2.12; 95% CI=1.02–
4.41). In Caucasian women, the combined GSTP1 105IV/VV and CYP1B1 119AA genotypes
resulted in a near 2-fold increase in risk (OR=1.96; 95% CI=1.04–3.72) and the three way
combination of GSTP1 105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes resulted in an
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almost 4-fold increase in risk (OR=3.97; 95% CI=1.27–12.40). These results suggest the
importance of estrogen/carcinogen metabolic enzymes in the etiology of breast cancer, especially
in women before the age of 60, as well as preventative measures such as smoking cessation.
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Introduction
Breast cancer is the second leading cause of cancer-related deaths among American women,
with ~40,500 deaths expected this year alone (1). As less than half of breast cancer cases can
be accounted for by known risk factors (2), there is a great need for continuing research on
the etiological basis of breast carcinogenesis.
The potential involvement of environmental carcinogens in breast carcinogenesis is
supported by in vitro and in vivo animal studies (3,4). Typically, the parent compound itself
is inert although it can produce reactive metabolites that bind covalently to DNA following
phase I enzyme metabolism. Breast tissue has been shown to be capable of this metabolic
activation (5,6). Environmental contaminants are not the only source of reactive metabolites
and the importance of endogenous estrogen exposure in lifetime breast cancer risk is well
established. Estrogen can have an initiating as well as a promoting effect in breast
carcinogenesis, through its DNA damaging capabilities as well as its ability to stimulate
proliferative activity in mammary epithelial cells (7). Circulating estrogens are not the only
source of exposure as breast tissue is capable of estrogen synthesis (8,9), creating a region of
localized exposure (10).
The metabolism of environmental carcinogens and estrogen is carried out in part by the
phase I and phase II enzymes. The phase I enzyme, cytochrome P450 1B1 (CYP1B1), is
highly expressed in breast tissue (11) and plays an important role in estrogen as well as
polycyclic aromatic hydrocarbon (PAH) and arylamine metabolism (12,13). Its predominant
4-hydroxylation of estrogen (6) results in the production of the ultimate carcinogenic
metabolite, the depurinating quinone, as well as reactive oxygen species as reviewed by
Cavalieri et al (14). It has recently been shown in vitro that CYP1B1 is the enzyme involved
in the metabolism of estradiol to guanine and adenine adduct forming compounds,
supporting its involvement in mammary carcinogenesis (15). Following oxidative
metabolism and the activation by phase I enzymes, the phase II enzymes mediate
detoxification of the reactive phase I metabolites. Glutathione S-transferases (GSTs) - such
as GSTM1, GSTT1 and GSTP1-conjugate electrophilic compounds with glutathione
rendering them less carcinogenic. Genetic polymorphisms, which can alter the activation
and detoxification capabilities of these enzymes, could potentially influence the individual
risk for breast cancer, as they may increase the amount of activated metabolites.
A single nucleotide polymorphism (SNP) in the CYP1B1 gene, which results in an amino
acid substitution of L432V in the heme binding region, has been reported to alter the
catalytic activity of the enzyme, producing a higher ratio of 4-OH to 2-OH catecholestrogen
metabolites (16,17). However, other studies have not confirmed these findings (18). The
A119S SNP does not appear to have as great a singular impact on the enzyme kinetics
related to catecholestrogen metabolism (19). Haplotype analyses of the 119S and 432L
allele, however, demonstrated a 1.2–1.5-fold increase in the activation of some PAHs
compared to three other haplotypes (17), although the codon 48 and 119 linkage was not
considered.
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Polymorphisms in the phase II enzymes GSTM1, GSTT1, and GSTP1 also have known
functional implications. The polymorphisms in GSTM1 and GSTT1 consist of deletions of
the genes, resulting in a loss of expression and therefore loss of function (20). Individuals
with the null alleles have a decreased capacity to metabolize the enzyme's respective
substrates. The GSTP1 gene has two SNPs, I105V and A114V, which can affect enzyme
activity depending on the substrate (20).
As variations in the ability to metabolize estrogen and carcinogens may be part of breast
cancer etiology, the association of these polymorphisms with breast cancer risk has been the
focus of multiple studies. Associations with breast cancer have been found in some studies
(21,22), although these findings have generally not been confirmed by other laboratories
(23–25). In some studies, analyzing individual genotypes did not demonstrate an association
with risk for breast cancer, but including combinations of genotypes (26,27) or genotypes
and menopausal status (28) demonstrated an increase in risk for breast cancer.
Subpopulation analyses, such as in post-menopausal women, demonstrated an association
with the GSTM1 polymorphism and breast cancer (27,28). A pooled meta-analysis found a
slight increase in risk associated with the CYP1B1 432VV genotype (29).
Gene/environmental interaction studies have produced notable results. Studies focusing on
CYP1B1 SNPs showed that the 432V allele was associated with breast cancer when
smoking, body mass index (BMI), or hormone replacement therapy use were included in
French and Finnish (30,31), Turkish (32) and Swedish (33) populations, respectively.
Interactions with the phase II enzymes and smoking (22,34), alcohol consumption (27,35)
and family history (36) have also been noted in these studies, though have not been
confirmed in other laboratories (24,25,37). In light of these findings, this study utilized a
case-control study design to determine if metabolic enzyme polymorphisms identified in
Caucasian and African-American women interact with age, family history, smoking and
each other to influence breast cancer risk.
Materials and methods
Study populations
The population in this study is similar to one previously described (38). Breast cancer cases
were initially recruited at the Breast Care Center at the North Carolina Baptist Hospital with
additional cases recruited at the Moses H. Cone Memorial Hospital and the University of
North Carolina (UNC) at Chapel Hill, Lineberger Comprehensive Cancer Center from
ongoing studies conducted from November 1998 to May 2004. Cancer-free controls were
recruited from women undergoing routine mammography screening at the Breast Screening
and Diagnostic Center of the Comprehensive Cancer Center at Wake Forest University
Baptist Medical Center. Controls were frequency-matched to cases by age (±5 years) and
race. Controls were excluded if they had any previous history of cancer, chronic
inflammatory diseases and abnormal current mammogram results. Eligibility requirements
for cases and controls were designated as at least 18 years of age, English speaking, capable
of comprehending informed consent and no history of other cancers, including skin cancer.
Each participant was given a detailed description of the study protocol and signed her
informed consent as approved by each of the institution's Institutional Review Boards.
Following consent, a 20 ml blood sample was collected and each woman was given a self-
administered questionnaire regarding demographic information, established breast cancer
risk factors, medical and family history. The case-control status was confirmed by medical
records and pathology reports.
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DNA was isolated from each blood sample using the QIAamp® DNA Blood mini kit
(Qiagen, Valencia, CA), as described in the manufacturer's protocol, for use in molecular
genotyping of the metabolic enzymes. Two hundred microliters of blood was eluted in a
final volume of 200 µl that, according to the manufacturer, yields 15–60 ng/µl of DNA.
DNA from UNC breast cancer patient samples were obtained from lymphoblastoid cell lines
as described previously (39). Paraffin-embedded tissue (PET) samples from breast cancer
patients were used for DNA isolation in the event there was insufficient DNA isolated from
the blood samples. In these cases, tissue from the block was de-paraffinized and digested in
a buffer as described previously (40).
Each genotype was analyzed following polymerase chain reaction (PCR). The PCR reaction
mixtures consisted of 2.5 mM MgCl2, 0.2 or 0.25 (GSTM1/T1 PET) mM dNTP mix
(Promega, Madison, WI), 0.2 µM of respective primers, 1–2 units of either AmpliTaq
Polymerase Gold (Applied Biosystems, Foster City, CA) or Taq DNA polymerase
(Eppendorf, Westbury, NY) along with their manufacturer's supplied buffer mix and 2 µl of
template DNA. Primer sequences have been described previously (40).
A modification of a previously used multiplex PCR was used for genotyping GSTM1 and
GSTT1 (41,42) by analyzing for the presence of the GSTT1 (480 bp), GSTM1 (231 bp) and
the PCR control GSTM4 (158 bp) bands. This procedure was modified for use with paraffin-
embedded tissue and some blood samples, which utilized different primers for GSTT1 (111
bp product) and used the β-globin (268 bp) gene as the control for amplification (43,44).
The GSTP1 I105V SNP was initially analyzed using PCR/restriction fragment length
polymorphism. The PCR product was digested in a 30 µl reaction consisting of 20 U of
BsmB1 and supplied buffer (NE Biolabs, Beverly, MA) and analyzed for the wild-type 166
bp fragment or variant 94 and 72 bp fragments.
PCR followed by single-strand conformation polymorphism (SSCP) analysis was initially
used for the genotyping of the A119S and L432V alleles of CYP1B1 (primers previously
described) (21) as well as A114V of GSTP1. For each SSCP analysis, the PCR products
were denatured and analyzed using the GenePhor electrophoresis unit (Amersham
Biosciences, Piscataway, NJ) followed by staining with Plus One DNA Silver Staining kit
(Amersham Biosciences). A119S PCR products were separated on a GeneGel SSCP gel
rehydrated in GeneGel Clean 15/24 kit rehydration buffer maintained at 12°C. The L432V
PCR products were separated on a precast GeneGel Clean 15/24 gel rehydrated in a 15/24
kit rehydration buffer maintained at 10°C. The A114V PCR products were separated on a
precast GeneGel Clean 15/24 gel rehydrated in a Buffer B rehydration buffer maintained at
13°C. The variant and wild-type alleles were recognized by specific banding patterns on the
gel. Initial products were sequenced by the DNA Sequencing Core of the Wake Forest
University Biomolecular Resource Facility to confirm that the banding pattern corresponded
to the correct polymorphism. Further into the study, SNP analyses were completed using
MassARRAY® (Sequenom®, San Diego, CA) with the assistance of the Wake Forest
University School of Medicine, Center for Human Genomics as well as by sequencing by
the Biomolecular Resource Facility of Wake Forest University or MWG-Biotech Inc. (High
Point, NC).
Statistical analysis
P-values for demographic information were associated with the Student's t- or Chi-square
test. Genotype distributions were determined using the Chi-square or Fisher's exact test.
Odds ratios were obtained by using logistic regression models with and without modifying
covariates as indicated in each table. This was repeated for interaction models as well.
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Gene-gene interactions were analyzed using the MARS-logit model as described previously
(Lin et al: Proc Amer Assoc Cancer Res 2006 [abstract nr 1205]). Every frequency reported
was from a complete data set for each of the genotypes as well as each of the covariates
(age, family history, age at menarche, BMI, smoking history and age at first live birth)
without any missing values. Therefore, 349 cases and 363 controls met the criteria and were
included in the final model. Analyses were completed using the Statistical Analysis System
(SAS Institute, Cary, NC) and MARS 2.0 (Salford Systems, San Diego, CA) for the MARS-
logit analysis.
Results
This study included 541 cases and 635 controls. The demographic characteristics of this
population are described in Table I. The case and control populations were similar for most
criteria. Age, age at menarche, parity, BMI and smoking status showed no significant
difference between the cases and controls. There was a significant difference in the age of
first live birth as well as family history (FH) between cases and controls (P=0.019 and
0.007, respectively). Notably, cases were younger than controls at age at first live birth.
These two factors are believed to contribute to overall breast cancer risk (45). As there was a
significant difference in the distribution of race between the cases and controls (P=0.026),
further analyses were completed analyzing the Caucasian and African-American populations
independently. Among the demographic characteristics presented in Table I, age, family
history, age at menarche, age at first live birth, BMI and smoking status were used as
covariates in the adjusted odds ratios in Tables II–V. The CYP1B1 and GSTP1 genotypes
were in Hardy-Weinberg equilibrium for the two control populations. As heterozygosity was
not analyzed for GSTM1 and GSTT1, Hardy-Weinberg equilibrium could not be
determined.
The impact of each of the genotypes alone on breast cancer risk is described in Tables II and
III for Caucasians and African-Americans, respectively. There were no statistically
significant interactions between any of the genotypes and breast cancer in either Caucasians
or African-Americans. There was an indication of an increased risk for Caucasian women
homozygous for the valine allele at the GSTP1 114 locus (OR=2.17; 95% CI=0.19–25.10)
compared to 114AA, though this was not statistically significant (P=0.53). This
polymorphism has not been analyzed in most studies; however, in one previous study,
alleles containing the 114V polymorphism were shown to be protective against breast cancer
(46). African-American women who had at least one 119S allele in CYP1B1 exhibited a
protective effect compared to the 119AA alleles (OR=0.53; 95% CI=0.20–1.40), while
African-American women who had at least one valine allele at codon 432 appeared to
exhibit an increased breast cancer risk (OR=5.52; 95% CI=0.50–61.37), though neither of
these associations reached statistical significance.
Stratified analyses were used to determine if there were interactions between each of the
genotypes and age, family history and smoking history in the Caucasian and African-
American populations. The results are summarized in Tables IV and V. In the Caucasian
population, women with a history of smoking and the GSTP1 114V SNP had an
approximate 2-fold increase in breast cancer risk (OR=2.12; 95% CI=1.02–4.41), while in
non-smoking women there was no association. The women diagnosed on or before the age
of 60 with the CYP1B1 119SS alleles had a 3-fold increase in risk (OR=3.09; 95%CI=1.22–
7.84), while these alleles were protective in the older population. None of the
polymorphisms showed significant interactions with family history of breast cancer. In
African-Americans, the null GSTT1 genotype showed a significantly higher risk for breast
cancer among younger women (≤60) (OR=4.07, 95% CI=1.12–14.80). Due to a limited
sample size, this finding could not be replicated in the >60 age group. Also among African-
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Americans, the difference in ORs between never and ever smokers with the GSTP1 105VV
genotype approached significance (P=0.08) (OR=1.12, 95% CI=0.21–6.07 vs. OR=8.23
95% CI=0.77–88.30).
Potential gene-gene interactions were also explored to identify high-risk subpopulations
using the MARS-logit model as described previously (Lin HY et al: Proc Amer Assoc
Cancer Res 2006 [abstract nr 1205]). Fig. 1 shows the best predictive risk model for
Caucasians. In Caucasians, breast cancer risk was significantly higher in two groups of
subjects: i) A two-way interaction between GSTP1 105IV/VV and CYP1B1 119AA
genotypes (OR=1.96, 95%CI=1.04–3.72); ii) A three-way interaction between GSTP1
105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes (OR=3.97, 95% CI=1.27–
12.40).
Discussion
Early in vitro and in vivo animal studies suggest that breast carcinogenesis may result from
exposure to environmental agents (3,4). The cellular components of breast tissue make it an
ideal location for storage of known mammary genotoxins, as the abundance of fatty tissue in
the breast can contribute to the storage and concentration of lipophilic compounds such as
PAHs (47,48). This is supported by the frequent presence of aromatic DNA adducts in the
normal adjacent tissues of breast cancer cases than in a cancer free control population (49).
A major source of PAH exposure for those using cigarettes can be found in tobacco smoke
(50). The effects of smoking on breast cancer risk are controversial due to the potential for
anti-estrogenic effects (51). Based on results published during or before 2002, it was
concluded that smoking most likely did not decrease risk, though whether it increases risk is
still unclear (52). The GSTP1 enzyme is known to metabolize carcinogenic compounds such
as those found in cigarette smoke. Variations in the ability to metabolize these carcinogens
may impact the effects of cigarette smoking on breast cancer. The alteration of enzyme
activity as a result of the codon 105 SNP most likely is related to the structural effects at the
H-site (53,54). The 114 SNP, however, is not in the active site, though may have a minor
effect on enzyme activity (53,55).
As in several previous studies, no significant associations were found when examining
individual genotypes and breast cancer risk in either Caucasian or African-American
women. In the two populations of women examined in this study, the effect of the GSTP1
SNPs appeared to be modulated by smoking history. The Caucasian women exhibited a near
2-fold increase in risk in women that smoked and had the GSTP1 105VV alleles, though the
difference was not significant (P=0.33). A 2-fold increase in risk was also observed in
Caucasian women smokers with the 114V allele (OR=2.12; 95% CI=1.02–4.41). In African-
American women, an 8-fold increase in risk was observed in women with a history of
smoking and the GSTP1 105VV genotype, although not significant. Several studies have
analyzed the effect of the GSTP1 I105V SNP and smoking on breast cancer risk, though
these investigations have produced conflicting results (27,28,36). A pooled analysis of
Caucasian women found no association with any of the GSTP1 I105V genotypes alone or
when combined with smoking (25).
The CYP1B1 enzyme is one of the predominant cytochrome P450 isozymes responsible for
the metabolism of estrogen and PAHs in breast tissue (6,11,13). In this study, the CYP1B1
119SS genotype risk was significantly higher in younger Caucasian women (P=0.005), with
a 3-fold increase in risk associated with this population of women (≤60 years old). In
younger African-American women, risk was significantly higher in those with the GSTT1
null alleles. Breast cancer in young women, particularly those younger than 35 years, is
associated with a poorer prognosis (56,57). The differences in tumor histopathology and
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patient prognosis may be related to the poor differentiation of tumors, their higher grade and
the presence of mutations in tumor suppressor genes such as p53 (58,59). Recent studies
from our laboratory, utilizing a case-case study design, have demonstrated that combinations
of specific genotypes in phase I and phase II enzymes or interactions between specific
genotypes and smoking predisposed women to mutations in the p53 gene (40). The impact
of combinations of polymorphisms on risk of disease was explored in the Caucasian
population. Alone the GSTP1 105IV/VV genotype did not have much impact on breast
cancer risk, although in women with these alleles along with the CYP1B1 119AA genotype
an almost 2-fold increase in risk is observed. Breast cancer risk was increased nearly 4-fold
in women with the GSTP1 105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes.
These results suggest that women with specific combinations of SNPs, particularly in
combination with environmental or endogenous exposures, may be predisposed to an earlier
onset of the disease. Future studies with larger patient samples will be needed in order to
confirm and extend these findings.
The biological plausibility of the association of these polymorphisms, due to functional
effects on metabolism, and breast cancer risk supports the findings observed in this study.
The number of women included in this study was of sufficient size to analyze the interaction
of metabolic genotypes with potential risk factors in the Caucasian and African-American
women. One limitation of this study, however, was the small number of African-American
women recruited, which prevented analyses of the interactions between the genotypes. This
study focused on individual polymorphisms within genes containing multiple SNPs. Future
studies should include haplotype analyses, which would take into account the effects of the
SNPs when present on the same allele.
The results of this study provide further data demonstrating that individual genotypes may
not impact breast cancer risk, as no significant associations were noted in either the
Caucasian or African-American populations. There were interesting trends none-the-less
with the CYP1B1 SNPs in the African- American population that were not seen with the
Caucasian women. The differences between races were not surprising as it has been well
established that breast cancer incidence and prognosis differs between African-American
and Caucasian women (60). A recent study demonstrated that African- American women
more frequently exhibit the basal-like subtype of breast cancer, which is associated with a
poorer prognosis (61).
In contrast, combining genotypes with each other as well as other plausible breast cancer
risk factors did provide notable findings. We noted that the less common GSTP1 A114V
SNP genotypes exhibited a trend towards an increased breast cancer risk in Caucasian
women who smoked. The significant interactions between the CYP1B1 A119S SNP and age
of diagnosis may give some insight into the etiology of breast cancer in women diagnosed
before the age of 60. Additional studies would be required to determine the mechanism
behind this association. As there are not many studies that focus on either of these
polymorphisms, further studies would be required in order to conclude that there is truly an
association with breast cancer risk. The interactions among the phase I and phase II enzyme
polymorphisms support the concept that genetic alterations in the ability to activate and
detoxify potential breast carcinogens can influence cancer risk. This information is vital in
understanding the etiology of this disease, which can assist in the generation of effective
breast cancer prevention strategies.
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Table I
Demographic characteristics of the study population.





Age (years) Mean ± S.D. 58.03±12.95 59.10±1.56 0.140
≤50 158 (29.2) 169 (26.6) 0.211
51–60 147 (27.2) 154 (24.3)
61–70 121 (22.4) 173 (27.2)
>70 115 (21.3) 139 (21.9)
Race African-American 63 (11.8) 103 (16.4) 0.026
Caucasian 469 (88.2) 524 (83.6)
Others 9 8
Family history None 411 (76.5) 524 (82.9) 0.007
Mother and/or Sister 126 (23.5) 108 (17.1)
Missing 4 3
Age at menarche ≤12 240 (45.4) 286 (45.6) 0.129
12.5–14 210 (39.8) 272 (43.4)
≥14.5 78 (14.8) 69 (11.0)
Missing 13 8
Parity Nulliparous 75 (14.0) 88 (13.9) 0.954
≥1 460 (86.0) 545 (86.1)
Missing 6 2
Age at first live birth Nulliparous 75 (14.0) 88 (14.0) 0.019
≤24 308 (57.6) 310 (49.3)
24.5–29 102 (19.1) 150 (23.9)
≥29.5 50 (9.4) 81 (12.9)
Missing 6 6
Body mass index (kg/m2) Mean ± S.D. 27.79±6.15 27.29±5.79 0.155
Smoking status Never 319 (59.6) 361 (57.1) 0.180
Former 143 (26.7) 198 (31.3)
Current 73 (13.6) 73 (11.6)
Missing 6 3
a
P-value associated with either the Student's t- or Chi-square test, others and missing values are not included in the tests.
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Table II
Drug-metabolism genotypes in Caucasian breast cancer cases and controls.
Genes Genotype Controls Cases
GSTM1 Wild-type 198 185
Null 268 206
OR (95% CI)a 0.82 (0.60–1.11)
P-valueb 0.157
GSTT1 Wild-type 384 322
Null 82 69
OR (95% CI)a 1.08 (0.72–1.62)
P-valueb 0.985
GSTP1 II 179 160
I105V IV 179 183
VV 35 42
IV vs. II OR (95% CI)a 1.22 (0.87–1.71)
VV vs. II OR (95% CI)a 1.46 (0.84–2.54)
IV/VV vs. II OR (95% CI)a 1.26 (0.91–1.74)
VV vs. II/IV OR (95% CI)a 1.31 (0.77–2.22)
P-valueb 0.435
GSTP1 AA 337 328
A114V AV 47 56
VV 1 2
AV vs. AA OR (95% CI)a 1.37 (0.87–2.18)
VV vs. AA OR (95% CI)a 2.17 (0.19–25.10)
AV/VV vs. AA OR (95% CI)a 1.39 (0.88–2.19)
VV vs. AA/AV OR (95% CI)a 2.08 (0.18–24.13)
P-valueb 0.527
CYP1B1 AA 201 199
A119S AS 173 148
SS 32 32
AS vs. AA OR (95% CI)a 0.83 (0.60–1.16)
SS vs. AA OR (95% CI)a 1.09 (0.60–1.99)
AS/SS vs. AA OR (95% CI)a 0.87 (0.64–1.19)
SS vs. AA/AS OR (95% CI)a 1.18 (0.66–2.12)
P-valueb 0.598
CYP1B1 LL 149 121
L432V LV 188 184
VV 75 76
LV vs. LL OR (95% CI)a 1.24 (0.87–1.76)
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Genes Genotype Controls Cases
VV vs. LL OR (95% CI)a 1.29 (0.83–2.01)
LV/VV vs. LL OR (95% CI)a 1.25 (0.90–1.74)
VV vs. LL/LV OR (95% CI)a 1.14 (0.77–1.69)
P-valueb 0.418
a
Odds Ratio (OR) adjusted for age, family history, smoking history, age at menarche, age at first live birth and body mass index using logistic
regression.
b
Chi-square or Fisher's exact test for genotype distributions.
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Table III
Drug-metabolism genotypes in African-American breast cancer cases and controls.
Genes Genotype Controls Cases
GSTM1 Wild-type 59 37
Null 28 19
OR (95% CI)a 1.35 (0.57–3.15)
P-valueb 0.828
GSTT1 Wild-type 71 41
Null 16 15
OR (95% CI)a 2.37 (0.86–6.55)
P-valueb 0.234
GSTP1 II 25 14
I105V IV 39 29
VV 13 13
IV vs. II OR (95% CI)a 1.01 (0.39–2.67)
VV vs. II OR (95% CI)a 1.74 (0.48–6.26)
IV/VV vs. II OR (95% CI)a 1.14 (0.45–2.90)
VV vs. II/IV OR (95% CI)a 1.72 (0.57–5.18)
P-valueb 0.525
GSTP1 AA 70 49
A114V AV 4 5
VV - -
AV vs. AA OR (95% CI)a 1.48 (0.33–6.65)
VV vs. AA OR (95% CI)a -
AV/VV vs. AA OR (95% CI)a 1.48 (0.33–6.65)
VV vs. AA/AV OR (95% CI)a -
P-valueb 0.492
CYP1B1 AA 17 19
A119S AS 41 21
SS 19 15
AS vs. AA OR (95% CI)a 0.51 (0.18–1.45)
SS vs. AA OR (95% CI)a 0.57 (0.18–1.79)
AS/SS vs. AA OR (95% CI)a 0.53 (0.20–1.40)
SS vs. AA/AS OR (95% CI)a 0.88 (0.35–2.22)
P-valueb 0.177
CYP1B1 LL 6 1
L432V LV 28 23
VV 43 28
LV vs. LL OR (95% CI)a 6.96 (0.58–83.48)
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Genes Genotype Controls Cases
VV vs. LL OR (95% CI)a 4.88 (0.43–55.87)
LV/VV vs. LL OR (95% CI)a 5.52 (0.50–61.37)
VV vs. LL/LV OR (95% CI)a 0.87 (0.38–1.99)
P-valueb 0.316
a
Odds ratio (OR) adjusted for age, family history, smoking history, age at menarche, age at first live birth and body mass index using logistic
regression.
b
Chi-square or Fisher's exact test for genotype distributions.
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